Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival benefit remains consistent in all subgroups, including in patients with stage II tumors,...